Information Provided By: 
Fly News Breaks for April 8, 2015
TEVA, MYL
Apr 8, 2015 | 07:16 EDT
JPMorgan says Mylan (MYL) is one the cheapest names in its Specialty Pharma coverage universe. The firm sees an "increasingly attractive set-up" for the stock given Mylan's "solid' earnings growth prospects, an "inexpensive" valuation and "significant" M&A optionality. It raised its price target for shares to $70 from $66 and reiterates an Overweight rating on the name. JPMorgan adds that it sees "solid strategic and financial rational" for a potential Teva (TEVA) acquisition of Mylan. It assumes a takeout price of $80 per share or above.
News For MYL;TEVA From the Last 2 Days
There are no results for your query MYL;TEVA
